Double-blind, randomized crossover study of intravenous infusion of magnesium sulfate versus 5% dextrose on depressive symptoms in adults with treatment-resistant depression

Syed M A Mehdi, Steven E. Atlas, Sidra Qadir, Dominique Musselman, Sharon Goldberg, Judi Woolger, Raul Corredor, Muhammad H. Abbas, Leopoldo Arosemena, Simone Caccamo, Carmen S G Campbell, Ashar Farooqi, Jinrun Gao, Janet Konefal, Lucas C. Lages, Laura Lantigua, Johanna Lopez, Vanessa Padilla, Ammar Rasul, Anna M. Ray & 3 others Herbert G. Simões, Eduard Tiozzo, John E Lewis

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aim: Treatment-resistant depression patients are more likely to suffer from comorbid physical and mental disorders, experience marked and protracted functional impairment, and incur higher health-care costs than non-affected individuals. Magnesium sulfate is a treatment option that may offer great potential for patients with treatment-resistant depression based on prior work in animals and humans. Methods: Twelve subjects with mild or moderate treatment-resistant depression were randomized into a double-blind crossover trial to receive an infusion of 4g of magnesium sulfate in 5% dextrose or placebo infusion of 5% dextrose with a 5-day washout in between the 8-day intervention period. Subjects were assessed before and after the intervention for serum and urine magnesium, lipid panel, the Hamilton Rating Scale for Depression, and the Patient Health Questionnaire-9. Results: We found a difference in serum magnesium from day 2 to 8 (pre-infusion) (P< 0.002) and from baseline to day 8 (P< 0.02). No changes were noted on the Hamilton Rating Scale for Depression or the Patient Health Questionnaire-9 24h post-treatment, but as serum magnesium increased from baseline to day 7, the Patient Health Questionnaire-9 decreased from baseline to day 7 (P=0.02). Conclusion: Magnesium sulfate did not significantly affect depression 24h post-infusion, but other results were consistent with the literature. The association between changes in serum magnesium and the Patient Health Questionnaire-9 supports the idea that magnesium sulfate may be used to address treatment-resistant depression, an ongoing medical challenge.

Original languageEnglish (US)
JournalPsychiatry and Clinical Neurosciences
DOIs
StateAccepted/In press - 2016

Fingerprint

Treatment-Resistant Depressive Disorder
Magnesium Sulfate
Intravenous Infusions
Cross-Over Studies
Depression
Glucose
Magnesium
Health
Serum
Mental Disorders
Health Care Costs
Placebos
Urine
Lipids
Surveys and Questionnaires
Therapeutics

Keywords

  • Depressive symptoms
  • Intervention study
  • Intravenous infusions
  • Magnesium sulfate
  • Treatment-resistant depression

ASJC Scopus subject areas

  • Neuroscience(all)
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Double-blind, randomized crossover study of intravenous infusion of magnesium sulfate versus 5% dextrose on depressive symptoms in adults with treatment-resistant depression. / Mehdi, Syed M A; Atlas, Steven E.; Qadir, Sidra; Musselman, Dominique; Goldberg, Sharon; Woolger, Judi; Corredor, Raul; Abbas, Muhammad H.; Arosemena, Leopoldo; Caccamo, Simone; Campbell, Carmen S G; Farooqi, Ashar; Gao, Jinrun; Konefal, Janet; Lages, Lucas C.; Lantigua, Laura; Lopez, Johanna; Padilla, Vanessa; Rasul, Ammar; Ray, Anna M.; Simões, Herbert G.; Tiozzo, Eduard; Lewis, John E.

In: Psychiatry and Clinical Neurosciences, 2016.

Research output: Contribution to journalArticle

Mehdi, SMA, Atlas, SE, Qadir, S, Musselman, D, Goldberg, S, Woolger, J, Corredor, R, Abbas, MH, Arosemena, L, Caccamo, S, Campbell, CSG, Farooqi, A, Gao, J, Konefal, J, Lages, LC, Lantigua, L, Lopez, J, Padilla, V, Rasul, A, Ray, AM, Simões, HG, Tiozzo, E & Lewis, JE 2016, 'Double-blind, randomized crossover study of intravenous infusion of magnesium sulfate versus 5% dextrose on depressive symptoms in adults with treatment-resistant depression', Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.12480
Mehdi, Syed M A ; Atlas, Steven E. ; Qadir, Sidra ; Musselman, Dominique ; Goldberg, Sharon ; Woolger, Judi ; Corredor, Raul ; Abbas, Muhammad H. ; Arosemena, Leopoldo ; Caccamo, Simone ; Campbell, Carmen S G ; Farooqi, Ashar ; Gao, Jinrun ; Konefal, Janet ; Lages, Lucas C. ; Lantigua, Laura ; Lopez, Johanna ; Padilla, Vanessa ; Rasul, Ammar ; Ray, Anna M. ; Simões, Herbert G. ; Tiozzo, Eduard ; Lewis, John E. / Double-blind, randomized crossover study of intravenous infusion of magnesium sulfate versus 5% dextrose on depressive symptoms in adults with treatment-resistant depression. In: Psychiatry and Clinical Neurosciences. 2016.
@article{eafb677801a6410ab8a3c659440f5bc6,
title = "Double-blind, randomized crossover study of intravenous infusion of magnesium sulfate versus 5{\%} dextrose on depressive symptoms in adults with treatment-resistant depression",
abstract = "Aim: Treatment-resistant depression patients are more likely to suffer from comorbid physical and mental disorders, experience marked and protracted functional impairment, and incur higher health-care costs than non-affected individuals. Magnesium sulfate is a treatment option that may offer great potential for patients with treatment-resistant depression based on prior work in animals and humans. Methods: Twelve subjects with mild or moderate treatment-resistant depression were randomized into a double-blind crossover trial to receive an infusion of 4g of magnesium sulfate in 5{\%} dextrose or placebo infusion of 5{\%} dextrose with a 5-day washout in between the 8-day intervention period. Subjects were assessed before and after the intervention for serum and urine magnesium, lipid panel, the Hamilton Rating Scale for Depression, and the Patient Health Questionnaire-9. Results: We found a difference in serum magnesium from day 2 to 8 (pre-infusion) (P< 0.002) and from baseline to day 8 (P< 0.02). No changes were noted on the Hamilton Rating Scale for Depression or the Patient Health Questionnaire-9 24h post-treatment, but as serum magnesium increased from baseline to day 7, the Patient Health Questionnaire-9 decreased from baseline to day 7 (P=0.02). Conclusion: Magnesium sulfate did not significantly affect depression 24h post-infusion, but other results were consistent with the literature. The association between changes in serum magnesium and the Patient Health Questionnaire-9 supports the idea that magnesium sulfate may be used to address treatment-resistant depression, an ongoing medical challenge.",
keywords = "Depressive symptoms, Intervention study, Intravenous infusions, Magnesium sulfate, Treatment-resistant depression",
author = "Mehdi, {Syed M A} and Atlas, {Steven E.} and Sidra Qadir and Dominique Musselman and Sharon Goldberg and Judi Woolger and Raul Corredor and Abbas, {Muhammad H.} and Leopoldo Arosemena and Simone Caccamo and Campbell, {Carmen S G} and Ashar Farooqi and Jinrun Gao and Janet Konefal and Lages, {Lucas C.} and Laura Lantigua and Johanna Lopez and Vanessa Padilla and Ammar Rasul and Ray, {Anna M.} and Sim{\~o}es, {Herbert G.} and Eduard Tiozzo and Lewis, {John E}",
year = "2016",
doi = "10.1111/pcn.12480",
language = "English (US)",
journal = "Psychiatry and Clinical Neurosciences",
issn = "1323-1316",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Double-blind, randomized crossover study of intravenous infusion of magnesium sulfate versus 5% dextrose on depressive symptoms in adults with treatment-resistant depression

AU - Mehdi, Syed M A

AU - Atlas, Steven E.

AU - Qadir, Sidra

AU - Musselman, Dominique

AU - Goldberg, Sharon

AU - Woolger, Judi

AU - Corredor, Raul

AU - Abbas, Muhammad H.

AU - Arosemena, Leopoldo

AU - Caccamo, Simone

AU - Campbell, Carmen S G

AU - Farooqi, Ashar

AU - Gao, Jinrun

AU - Konefal, Janet

AU - Lages, Lucas C.

AU - Lantigua, Laura

AU - Lopez, Johanna

AU - Padilla, Vanessa

AU - Rasul, Ammar

AU - Ray, Anna M.

AU - Simões, Herbert G.

AU - Tiozzo, Eduard

AU - Lewis, John E

PY - 2016

Y1 - 2016

N2 - Aim: Treatment-resistant depression patients are more likely to suffer from comorbid physical and mental disorders, experience marked and protracted functional impairment, and incur higher health-care costs than non-affected individuals. Magnesium sulfate is a treatment option that may offer great potential for patients with treatment-resistant depression based on prior work in animals and humans. Methods: Twelve subjects with mild or moderate treatment-resistant depression were randomized into a double-blind crossover trial to receive an infusion of 4g of magnesium sulfate in 5% dextrose or placebo infusion of 5% dextrose with a 5-day washout in between the 8-day intervention period. Subjects were assessed before and after the intervention for serum and urine magnesium, lipid panel, the Hamilton Rating Scale for Depression, and the Patient Health Questionnaire-9. Results: We found a difference in serum magnesium from day 2 to 8 (pre-infusion) (P< 0.002) and from baseline to day 8 (P< 0.02). No changes were noted on the Hamilton Rating Scale for Depression or the Patient Health Questionnaire-9 24h post-treatment, but as serum magnesium increased from baseline to day 7, the Patient Health Questionnaire-9 decreased from baseline to day 7 (P=0.02). Conclusion: Magnesium sulfate did not significantly affect depression 24h post-infusion, but other results were consistent with the literature. The association between changes in serum magnesium and the Patient Health Questionnaire-9 supports the idea that magnesium sulfate may be used to address treatment-resistant depression, an ongoing medical challenge.

AB - Aim: Treatment-resistant depression patients are more likely to suffer from comorbid physical and mental disorders, experience marked and protracted functional impairment, and incur higher health-care costs than non-affected individuals. Magnesium sulfate is a treatment option that may offer great potential for patients with treatment-resistant depression based on prior work in animals and humans. Methods: Twelve subjects with mild or moderate treatment-resistant depression were randomized into a double-blind crossover trial to receive an infusion of 4g of magnesium sulfate in 5% dextrose or placebo infusion of 5% dextrose with a 5-day washout in between the 8-day intervention period. Subjects were assessed before and after the intervention for serum and urine magnesium, lipid panel, the Hamilton Rating Scale for Depression, and the Patient Health Questionnaire-9. Results: We found a difference in serum magnesium from day 2 to 8 (pre-infusion) (P< 0.002) and from baseline to day 8 (P< 0.02). No changes were noted on the Hamilton Rating Scale for Depression or the Patient Health Questionnaire-9 24h post-treatment, but as serum magnesium increased from baseline to day 7, the Patient Health Questionnaire-9 decreased from baseline to day 7 (P=0.02). Conclusion: Magnesium sulfate did not significantly affect depression 24h post-infusion, but other results were consistent with the literature. The association between changes in serum magnesium and the Patient Health Questionnaire-9 supports the idea that magnesium sulfate may be used to address treatment-resistant depression, an ongoing medical challenge.

KW - Depressive symptoms

KW - Intervention study

KW - Intravenous infusions

KW - Magnesium sulfate

KW - Treatment-resistant depression

UR - http://www.scopus.com/inward/record.url?scp=85007413626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007413626&partnerID=8YFLogxK

U2 - 10.1111/pcn.12480

DO - 10.1111/pcn.12480

M3 - Article

JO - Psychiatry and Clinical Neurosciences

JF - Psychiatry and Clinical Neurosciences

SN - 1323-1316

ER -